Harnessing aryl hydrocarbon receptor dynamics: Unveiling therapeutic pathways in esophageal squamous cell carcinoma

doi:10.5493/wjem.v14.i4.98599

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=0

Dec 20, 2024 (publication date) through Oct 31, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Exp Med. Dec 20, 2024; 14(4): 98599
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.98599

Harnessing aryl hydrocarbon receptor dynamics: Unveiling therapeutic pathways in esophageal squamous cell carcinoma

Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng

Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan

Wen-Rui Hao, Division of Cardiology, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan

Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan

Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan

Co-corresponding authors: Wen-Rui Hao and Tzu-Hurng Cheng.

Author contributions: Cheng CH and Hao WR wrote the paper; Hao WR and Cheng TH share equal responsibility for the overall integrity of this work and contributed equally to its completion. Hao WR and Cheng TH, as co-corresponding authors, contributed equally to the conceptualization and drafting of the manuscript, and collaboratively revised the content for important intellectual input; Cheng CH, Hao WR, and Cheng TH read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404328, Taiwan. thcheng@mail.cmu.edu.tw

Received: June 30, 2024
Revised: October 11, 2024
Accepted: October 24, 2024
Published online: December 20, 2024
Processing time: 122 Days and 17.2 Hours

Core Tip

Core Tip: This editorial highlighted the critical insights from the minireview by Rahmati et al on the role of aryl hydrocarbon receptor (AHR) in esophageal squamous cell carcinoma, especially with regards to the modulation of immune responses and the potential of AHR as a therapeutic target. By discussing these findings, this editorial highlighted the importance of AHR dynamics in the development of innovative treatment strategies for esophageal squamous cell carcinoma, paving the way for future research and clinical applications.